Who are Olanzapine+NK-1 RA+5-HT3 RA's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olanzapine-nk-1-ra-5-ht3-ra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Olanzapine+NK-1 RA+5-HT3 RA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olanzapine+NK-1 RA+5-HT3 RA (Olanzapine+NK-1 RA+5-HT3 RA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antipsychotic + antiemetic. Area: Oncology (supportive care) / Psychiatry.

phase 3 Combination antipsychotic + antiemetic Dopamine D2, serotonin 5-HT2A (olanzapine); Substance P/NK-1 receptor (NK-1 RA); 5-HT3 receptor (5-HT3 RA) Oncology (supportive care) / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Olanzapine+NK-1 RA+5-HT3 RA (Olanzapine+NK-1 RA+5-HT3 RA) — Fifth Affiliated Hospital, Sun Yat-Sen University. This combination blocks dopamine/serotonin (olanzapine), substance P signaling (NK-1 RA), and serotonin 5-HT3 receptors to reduce nausea, vomiting, and potentially improve psychiatric symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Olanzapine+NK-1 RA+5-HT3 RA TARGET	Olanzapine+NK-1 RA+5-HT3 RA	Fifth Affiliated Hospital, Sun Yat-Sen University	phase 3	Combination antipsychotic + antiemetic	Dopamine D2, serotonin 5-HT2A (olanzapine); Substance P/NK-1 receptor (NK-1 RA); 5-HT3 receptor (5-HT3 RA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antipsychotic + antiemetic class)

Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olanzapine+NK-1 RA+5-HT3 RA — Competitive Intelligence Brief. https://druglandscape.com/ci/olanzapine-nk-1-ra-5-ht3-ra. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab